Sickle cell anemia (SCA) remains associated with high risks of morbidity and early death. Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for SCA. We report our experience with transplantation in a group of patients with the non-Black African variant and the Black African variant of SCA. This study included 40 consecutive SCA patients (13 patients with the non-Black African variant and 27 with the Black African variant) who underwent BM transplantation from HLA-identical sibling donors between June 2004 and May 2013, following a myeloablative-conditioning regimen. All patients obtained sustained engraftment. One patient (non-Black African variant) became a stable mixed chimera with 25% donor cells more than 6 years after transplantation. The probabilities of survival, SCA-free survival and TRM at 5 years after transplant were 91%, 91% and 9%, respectively. All surviving patients remained free of any SCA-related events after transplantation. Our results confirm that it is possible to offer a greater than 90% chance of cure to children with SCA. HSCT should be considered the standard of care for who have an HLA-identical donor, before complications result from the sickling of RBC.
INTRODUCTION
It has long been known that thalassemia can be cured with BM transplantation. 1, 2 It has become clear that sickle cell anemia (SCA) can be eradicated with the same transplant protocol as that used for thalassemia, which is based on BU and CY and includes GVHD prophylaxis with CsA. 3, 4 SCA is characterized by a cascade of events, beginning with the polymerization of HbS and the sickling of RBC. These events are followed by the occlusion of small and larger vessels due to the adherence of the sickle cells to the vascular endothelium, which leads to pain crises, stroke, acute chest syndrome and multiorgan failure as the most frequent SCA-related complications. 5 Sickle cell Hb (HbS) hemoglobinopathy falls into two major genetic patterns, which today are diffused without geographic restriction: patients of West African origin, predominantly of the Benin haplotype, and patients in Eastern Saudi Arabia and India, who are carriers of the Arab-Indian haplotype. Interactions between the genetic haplotypes and environmental orographic and socio-cultural characteristics influence the clinical phenotypes in various geographic locations. Therefore, SCA is not confined only to patients of Black African origin (for example, people of African-American descent), but can affect many other African-derived non-Black groups distributed throughout Italy, Greece, Turkey, Saudi Arabia, India, Pakistan, China and Latin America. Patients with the Black African SCA variant manifest a more severe form of SCA than patients with the non-Black African variant. [6] [7] [8] For patients with the Black African variant, painful crises, chest syndrome and stroke are more frequent and appear earlier in life, while patients with the nonblack African variant are more likely to become dependent on RBC transfusions.
Because SCA is a genetic disease of global public health significance, there is a moral imperative to utilize existing technology to cure this disease. Hematopoietic SCT (HSCT) is the only definitive cure for this genetic defect. Hematopoietic stem cells act as a cellular vector to transfer the normal gene into the hematopoietic system, which is replaced by the donor cells after transplantation. Permanent hematopoietic chimeras have been obtained after HSCT; these ex-SCA patients live a normal life. 9 Here we report our experience with transplantation in two patient groups: one with the non-Black African SCA variant (from Arabic countries), and one with the Black African variant (from Africa). All patients received transplants from an HLA-identical sibling.
PATIENTS AND METHODS
At the Mediterranean Institute of Hematology in Rome, all patients with SCA that were younger than 17 years and had an HLA-matched sibling donor were eligible for this study, which included 40 consecutive SCA patients (13 patients with the non-Black African variant and 27 with the Black African variant) who underwent BM transplantation from HLAidentical sibling donors between June 2004 and May 2013. Thirteen patients with the non-Black African SCA variant were treated with the original protocol used for class 1 and class 2 thalassemia patients, with the addition of anti-thymocyte globulin (here identified as Protocol 27). Twenty-seven patients with the Black African SCA variant were treated with a modification of our Protocol 26, which was in use for class 3 thalassemia patients 4 (here identified as Protocol 28). The institutional review board approved the treatment protocol, and all parents of patients provided written informed consent in accordance with the Declaration of Helsinki. 1 
Patient characteristics
Between 2004 and 2012, 13 patients with the non-Black African SCA variant prospectively enrolled in this study. The median patient age was 12 years (range 2-16 years). The median donor age was 13 years (range 2-28 years). Patient characteristics at the time of transplantation are summarized in Table 1 . All patients showed good performance status (Lansky/ Karnofsky 100) before transplantation. Five patients had a splenectomy before transplantation. All but one patient received chronic blood transfusions. The mean serum ferritin before transplantation was 1409 ± 784 ng/mL (mean ± s.d.). All but one patient received chronic blood transfusions before the first access at our Center. The mean of the baseline Hb level in the 13 non-Black African variants SCA was 6 ± 2 g/dL. The Hb level reported in Table 1 (9.9 ± 2.2 g/dL) was the mean level observed at the first access at our center. The vast majority of patients had hepatomegaly 42 cm, without presence of liver fibrosis and chelation history with deferoxamine (Desferal) or deferasirox (Exjade) started after chronic transfusion. The median ferritin level is relatively low in relationship to the median number of transfusions pre-transplant, suggesting the importance of chelation to prevent organ damage in view of transplant.
Before transplantation, eight patients had recurrent, painful, vasoocclusive crisis; four had acute chest syndrome; and one patient had hemorrhagic stroke. The cases unique patient number (UPN) 57 is a 2 years old child who never had any event related to SCA but received five transfusions pre-transplant for acute exacerbation of anemia occurring with acute splenic sequestration and transient RBC aplasia. The case UPN 137 is a 5 years old child who received sixty transfusions for acute anemia associated with sickle cell disease. In this patient, severe anemia (Hbo5 g/dL) also occurred with transient aplastic episodes due to temporary suppression of erythropoiesis given the significantly shortened lifespan of RBCs.
Between 2010 and 2013, 27 patients with the Black African SCA variant also enrolled in this study. The median patient age was 10 years (range 2-17 years), and the median donor age was 11 years (range 1-26 years). Patient characteristics at the time of transplantation are summarized in Table 2 . All patients showed good performance status (Lansky/Karnofsky 100) before transplantation. None of these patients had a splenectomy before transplantation. Only two patients received chronic blood transfusions, and the serum ferritin level before transplantation was 278 ± 231 ng/ mL (mean ± s.d.). Before transplantation, 11 patients had recurrent, painful, vaso-occlusive crisis; nine patients had recurrent painful crisis in association with acute chest syndrome; three patients experienced ischemic stroke and recurrent vaso-occlusive crisis; two patients experienced ischemic stroke; one patient exhibited leukocytosis; and one patient exhibited priapism.
All the patients received trimethoprim/sulfamethoxazole for pneumocystis prophylaxis were systematically assessed for G6PD deficiency during screening tests before transplant. All the patients were negative for G6PD deficiency. HLA typing at the molecular level was performed, and all donors for both groups were fully matched.
Molecular analyses
All 40 patients included in this study were molecularly analyzed before transplantation to confirm the presence of the homozygous condition for the point mutation at codon 6 (GAG4GTG, Glu4Val (HBB:c.20A4T)), which causes SCA, or to point out another β-globin gene defect associated with HbS (Hb D-Punjab at codon 121 GAA4CAA, Glu4Gln (HBB: c.364G4C)). Moreover, the α-globin gene defects and the polymorphism at − 158 bp of the G γ-gene promoter (HBG2:g.-158 C4T), which creates an XmnI restriction site, have been investigated. These modulating factors are considered responsible for diversity regarding the phenotypic severity of SCA. In fact, the coinheritance of an α-thalassemia gene (or, even more so, an increase of fetal Hb) can modify disease severity, mitigating the phenotype.
Genomic DNA was extracted from peripheral blood or marrow blood using the high-salt extraction procedure. The molecular analyses were performed using several PCR-based techniques (ARMS-PCR, gap PCR, restriction endonuclease analysis and direct DNA sequencing) depending on the defect being investigated. 10 Patients with the non-Black African SCA variant presented more frequently with the homozygous state for G γ -158 C4T, sometimes together with the -α 3.7 globin defect ( Table 1) . In contrast, patients with the Black African variant presented only a heterozygous condition for -α 3.7 in agreement with the described, more severe form of SCA (Table 2) .
Transplantation procedure
As a conditioning regimen, patients with non-Black African SCA received BU (14 mg/kg total dose), anti-thymocyte globulin (rabbit ATG thymoglobulin-Genzyme) 2.5 mg/kg for 4 days (10 mg/kg total dose) and CY (200 mg/kg total dose). From June 2006, patients with the non-Black African variant were given targeted i.v. BU. 11 Patients with the Black African variant received fludarabine (30 mg/m 2 /day) for 5 days and a conditioning regimen including targeted i.v. BU (14 mg/kg total dose) and CY (200 mg/ kg total dose).
All patients received CsA, low-dose methylprednisolone and a short course of MTX as GVHD prophylaxis. All patients received BM from HLAidentical sibling donors 36 h after the final dose of CY. All donors with sickle cell trait received hyperhydration and blood transfusion before the multiple marrow aspirations. In surgery, pre-operative transfusions are given to prevent peri-operative complications during BM aspirations in sickle cell trait donors. There is no consensus on the best regimen of transfusion for this purpose but we prefer to prevent eventually postoperative neurological complications, as reported. The diagnosis and degree of acute and chronic GVHD were assessed according to standard criteria. 3, 4 All patients were administered prophylactic broad-spectrum antibiotics and antifungal drugs until the neutrophil level exceeded 1.0 × 10 9 /L. Patients also received acyclovir as herpes virus prophylaxis and trimethoprim/sulfamethoxazole as Pneumocystis jiroveci prophylaxis. From the beginning of transplantation preparation until at least 100 days post transplantation, all patients were monitored weekly for the presence of EBV, CMV, adenovirus and BK virus in the blood and/or urine using sensitive reverse-transcriptase PCR.
Assessment of chimerism
The first chimerism analysis was performed on BM samples obtained 20 days after transplantation to determine the percentage of donor/ recipient DNA using PCR-based analysis of short tandem repeats. Subsequently, at 60, 90, 180 and 365 days post transplant, lineagespecific chimerism analysis was performed by PCR using fluorescent primers flanking a single informative short tandem repeat (AmpFLSTR Profiler Plus; Applera, CA, USA) that had been previously identified as polymorphic between the patient and the donor.
Statistical analysis
The probabilities of survival, SCA-free survival, rejection and mortality were calculated using the Kaplan-Meier estimator. 13 
RESULTS

Engraftment
For patients with the non-Black African SCA variant, the median time to neutrophil recovery (ANC ⩾ 500 × 10 9 /L) was 16 days (range 12-21 days), and the median time to a platelet count ⩾ 20 × 10 9 /L was 18 days (range 8-22 days). All patients had sustained engraftment with 100% donor chimerism, except for patient UPN 57, who showed a persistent mixed chimerism with 25% of donor cells (Table 3) . This patient had a progressive decrease in donor chimerism to 25%, starting 2 months after transplantation. She displayed stable mixed chimerism for more than 6 years without SCA-related events and never required transfusion after transplantation. All remaining patients exhibited full donor chimerism in the lymphoid and myeloid lineages. For the Black African SCA variant group, the median time to neutrophil recovery (ANC ⩾ 500 × 10 9 /L) was 16 days (range 11-23 days), and the median time to a platelet count ⩾ 20 × 10 9 /L was 17 days (range 11-22 days). All patients experienced sustained engraftment with 100% donor chimerism ( Table 4) . Acute and chronic GVHD Six patients with the non-Black African SCA variant developed grade 1-2 acute GVHD, and two patients developed grade 3 GVHD. Seven Black African variant patients developed grade 2 acute GVHD and five patients developed grade 3-4 GVHD. All patients in both variant groups responded promptly to the steroid treatment administered to control acute GVHD. At present, all Black African variant patients except one are off immunosuppressive medication. Chronic GVHD was observed in two Black African SCA variant patients: one patient developed bronchiolitis obliterans, and one patient had severe chronic GVHD with intestinal and hepatic involvement until death as a result of multiorgan failure at day +190 post transplantation. Cumulative incidence of grade 3-4 acute GVHD was 17.5%. Cumulative incidence of persistent severe chronic GVHD was 5%. 
Toxic and infectious complications
Among patients with the non-Black African variant, three had CsArelated neurotoxicity with seizures, without magnetic resonance imaging evidence of posterior reversible leukoencephalopathy, which required switching to tacrolimus (FK-500). No other significant toxic complications were observed in these patients. Nine patients had positive serology for CMV at the time of transplantation; all of these patients exhibited asymptomatic CMV reactivation, which was successfully treated with pre-emptive ganciclovir. Seven patients developed BK virus-related grade 2 hemorrhagic cystitis, which resolved with cidofovir therapy. One patient had a bacterial infection that was successfully treated with antibiotics. Among the Black African variant patients, six had CsA-related neurotoxicity with seizures. All patients received valproic acid (Depakin; Sanofi-Aventis, Milano, Italy) at a dose of 30 mg/kg per day in three divided doses starting at 24 h before the first BU administration. Many risk factors for the development of CsArelated neurotoxicity have been investigated in our patients, including arterial hypertension, fluid overload, hypercholesterolemia, hypomagnesaemia and pre-existing brain disease. In the screening examinations of these patients, the brain magnetic resonance imaging showed gliosis in 11/27 stroke-free Black African SCA patients (manuscript in preparation). The brain magnetic resonance imaging finding usually associated to CsArelated neurotoxicity was posterior reversible leukoencephalopathy syndrome, typically distributed in the posterior regions of the white matter of the brain. We cannot rule out that the preexisting brain disease in these patients might predispose to seizures during CsA treatment. In general, the prognosis of CsA neurotoxicity has been good and posterior leukoencephalopathy usually resolved completely with dose reduction or drug withdrawal. As alternative GVHD prophylaxis, we opted for tacrolimus. This calcineurin inhibitor, although similar to CsA in mechanism and metabolism, did not produce neurological side effects in these patients. All patients except one had positive serology for CMV before transplantation. Asymptomatic CMV reactivation occurred in 25 of 27 patients. All patients were provided pre-emptive antiviral therapy and none developed CMV disease. One patient had pneumonia due to aspergillosis, which resolved with antifungal therapy and surgical removal of the infected lung cavity; one patient experienced aspergillosis in the upper airway, which resolved with antifungal therapy. Seven patients developed BK virus-related grade 2 hemorrhagic cystitis, which resolved with cidofovir therapy.
Survival
All non-Black African variant patients survived without sickle cell disease, with Lansky/Karnofsky scores of 100. The probabilities of survival, SCA-free survival and TRP 5 years after transplantation were 100%, 100% and 0%, respectively. After transplantation, none of non-Black African variant patients experienced complications typical of SCA, such as pain, stroke or acute chest syndrome.
in total, 24 out of 27 Black African SCA patients survived without sickle cell disease, with Lansky/Karnofsky scores of 100. One patient died at 77 days post transplantation from complications of acute GVHD. One patients died from multiorgan failure at 190 days post transplantation. He had no steroid responsive grade 4 acute GVHD of gut and developed sepsis, which led to multiorgan failure and death. One patient died from complications of bronchiolitis obliterans at 445 days post transplantation. After transplantation, no Black African variant patients experienced complications typical of SCA, such as pain, stroke or acute chest syndrome.
The cumulative probabilities of survival, SCA-free survival and TRM were 91%, 91% and 9%, respectively (Figure 1 ).
DISCUSSION
Thalassemia was the first congenital hemoglobinopathy to be cured with the delivery of allogeneic cellular gene therapy obtained through HSCT. 1 The two drugs of choice for transplant preparation have traditionally been BU and CY. 9, 14 The second severe hemoglobinopathy to be radically cured with the same transplantation protocol was SCA. [15] [16] [17] [18] Migration from areas with high prevalence to areas with low or no prevalence in European countries has been growing during the last 20 years as a result of populations moving in an attempt to escape extreme poverty, and SCA has become the predominant genetic Hb disorder in the occidental part of the world. The Arab-Indian genetic haplotype and the Benin African haplotype are almost equally distributed today in Western countries. We have observed that the SCA phenotype cannot be restricted on the basis of genetic haplotype. The non-Black African SCA variant manifests with a less severe phenotype than the Black African variant. [6] [7] [8] Children with Black African variant SCA were prone to invasive infections caused by Streptococcus pneumonia, Haemophilus influenzae and Plasmodium falciparum (in malaria areas). Malaria is more endemic in Black African areas and therefore malaria is more common in black SCA patients. In Africa, malaria contributes substantially to the early mortality of patients with SCA. The progressive splenic hypofunction due to repeated infarcts leads to the breakdown of acquired immunity. P. falciparum therefore is capable of infecting HbSS cells in vivo in the absence of acquired immunity. So, the HbS advantage appears to be lost when acquired immunity is defective. For these reasons, we preferred in this population fludarabine-based preparative protocols, well tolerated, with less immunosuppression and minimal toxicity respect ATG.
Although thousands of transplants for thalassemia have been reported by numerous transplant centers around the world, not more than 400 transplants for SCA have been reported; nearly all of these reports summarize multicenter experiences. [15] [16] [17] [18] [19] [20] [21] [22] [23] The results of several major studies summarized in Table 5 show an OS of 490% and an EFS of 480%.
The morbidity and mortality associated with SCA are much more frequent and severe than those associated with thalassemia. There is an urgent need for a systematic approach to allogeneic 93%  94%  100%  92%  97%  90%  DFS  85%  84%  90%  86%  85%  90%  Rejection  10%  10%  9%  5%  13%  10% Abbreviation: DFS = disease-free survival; OS = overall survival.
SCT for sickle cell anemia G Lucarelli et al cellular gene therapy for SCA. Professionals working in transplant centers must interact with professionals working with large communities of SCA patients who have experience in the fight against this terrible congenital disease. The long experience of our group with transplantation for hemoglobinopathies and the vast experience of the Nigerian groups in Abuja and Lagos are the basis of our cooperation. This collaboration has led to our decision to pursue transplantation with all children who have an HLAidentical donor as soon as possible, before complications manifest in the SCA patient.
